Total Payments
$34,818
2024 Payments
$3,783
Companies
94
Transactions
1,451
Medicare Patients
6,243
Medicare Billing
$869,671
Payment Breakdown by Category
Food & Beverage$25,803 (74.1%)
Other$6,666 (19.1%)
Education$1,024 (2.9%)
Consulting$750.00 (2.2%)
Travel$575.41 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $25,803 | 1,401 | 74.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,200 | 1 | 9.2% |
| Honoraria | $2,000 | 1 | 5.7% |
| Long term medical supply or device loan | $1,466 | 17 | 4.2% |
| Education | $1,024 | 26 | 2.9% |
| Consulting Fee | $750.00 | 1 | 2.2% |
| Travel and Lodging | $575.41 | 4 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Rigel Pharmaceuticals, Inc. | $3,836 | 13 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $3,816 | 179 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,593 | 119 | $0 (2024) |
| AMAG Pharmaceuticals, Inc. | $2,276 | 6 | $0 (2018) |
| Amgen Inc. | $1,740 | 105 | $0 (2023) |
| Exelixis Inc. | $1,581 | 41 | $0 (2024) |
| GENZYME CORPORATION | $1,265 | 51 | $0 (2024) |
| Genentech USA, Inc. | $1,119 | 83 | $0 (2024) |
| PFIZER INC. | $1,111 | 79 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,073 | 59 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,783 | 146 | Novartis Pharmaceuticals Corporation ($1,326) |
| 2023 | $4,848 | 220 | Novartis Pharmaceuticals Corporation ($663.78) |
| 2022 | $4,558 | 210 | Novartis Pharmaceuticals Corporation ($485.01) |
| 2021 | $2,758 | 132 | Amgen Inc. ($240.69) |
| 2020 | $1,590 | 83 | Amgen Inc. ($311.92) |
| 2019 | $6,780 | 201 | Rigel Pharmaceuticals, Inc. ($3,714) |
| 2018 | $5,909 | 212 | AMAG Pharmaceuticals, Inc. ($2,245) |
| 2017 | $4,593 | 247 | Exelixis Inc. ($830.54) |
All Payment Transactions
1,451 individual payment records from CMS Open Payments — Page 1 of 59
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $22.63 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $25.12 | General |
| Category: Oncology | ||||||
| 12/16/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $13.29 | General |
| Category: DESMOID TUMORS | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.26 | General |
| 12/09/2024 | Genentech USA, Inc. | Tecentriq (Biological), Tecentriq Hybreza | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: BioOncology | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $28.93 | General |
| Category: Oncology | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $13.61 | General |
| 11/27/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $33.20 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $23.56 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), REBLOZYL, WELIREG | Food and Beverage | In-kind items and services | $33.25 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.69 | General |
| Category: Hematology | ||||||
| 11/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $31.16 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.86 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $29.25 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $1.43 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $25.15 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $4.54 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $24.82 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $21.51 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.57 | General |
| 10/28/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 1,257 | 1,984 | $286,194 | $174,217 |
| 2022 | 10 | 1,559 | 2,153 | $313,290 | $183,570 |
| 2021 | 9 | 1,241 | 2,132 | $298,267 | $191,985 |
| 2020 | 29 | 2,186 | 64,242 | $856,863 | $319,900 |
Total Patients
6,243
Total Services
70,511
Medicare Billing
$869,671
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 434 | 991 | $133,785 | $89,043 | 66.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 392 | 503 | $45,270 | $30,725 | 67.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 196 | 196 | $51,156 | $26,654 | 52.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 49 | 53 | $9,646 | $6,244 | 64.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 59 | 59 | $12,272 | $6,202 | 50.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 38 | 38 | $13,072 | $4,949 | 37.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 40 | 81 | $10,206 | $4,850 | 47.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 35 | 49 | $8,869 | $4,453 | 50.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 14 | 14 | $1,918 | $1,097 | 57.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 502 | 885 | $119,475 | $75,473 | 63.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 263 | 263 | $68,643 | $37,841 | 55.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 487 | 644 | $57,960 | $36,846 | 63.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 76 | 89 | $16,198 | $10,899 | 67.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 90 | 90 | $18,720 | $8,990 | 48.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 43 | 43 | $14,792 | $6,245 | 42.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 45 | $8,145 | $3,447 | 42.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 41 | 63 | $7,938 | $3,248 | 40.9% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 11 | 14 | $994.00 | $406.93 | 40.9% |
| 99421 | Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | Office | 2022 | 16 | 17 | $425.00 | $174.24 | 41.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 331 | 809 | $109,215 | $73,338 | 67.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 375 | 713 | $64,170 | $46,365 | 72.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 203 | 203 | $52,983 | $32,566 | 61.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 110 | 110 | $22,941 | $13,178 | 57.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 87 | 99 | $18,018 | $13,091 | 72.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 40 | 40 | $13,760 | $5,931 | 43.1% |
About Dr. Sridhar Bolla, M.D
Dr. Sridhar Bolla, M.D is a Hematology & Oncology healthcare provider based in Avon, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316994148.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sridhar Bolla, M.D has received a total of $34,818 in payments from pharmaceutical and medical device companies, with $3,783 received in 2024. These payments were reported across 1,451 transactions from 94 companies. The most common payment nature is "Food and Beverage" ($25,803).
As a Medicare-enrolled provider, Bolla has provided services to 6,243 Medicare beneficiaries, totaling 70,511 services with total Medicare billing of $869,671. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Avon, IN
- Active Since 05/27/2006
- Last Updated 09/17/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1316994148
Products in Payments
- Tavalisse (Drug) $3,800
- FERAHEME (Drug) $2,276
- OPDIVO (Biological) $1,763
- KISQALI (Drug) $1,644
- Cabometyx (Drug) $1,106
- KEYTRUDA (Biological) $960.92
- JEVTANA (Drug) $847.66
- Lenvima (Drug) $752.05
- Abraxane (Drug) $489.34
- JAKAFI (Drug) $487.43
- CABOMETYX (Drug) $451.00
- INJECTAFER (Drug) $442.27
- REBLOZYL (Biological) $406.61
- IMBRUVICA (Drug) $389.20
- XARELTO (Drug) $381.11
- AFINITOR (Drug) $373.43
- LIBTAYO (Biological) $351.47
- CYRAMZA (Drug) $351.19
- LYNPARZA (Drug) $345.81
- PROMACTA (Drug) $334.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.